Mushroom supplement with immunotherapy for liver cancer
Part of Cancer, Digestive system clinical trials.
This study tests whether a mushroom extract called AHCC, taken as a supplement, can help the body's immune system work better when you receive immunotherapy for liver cancer. It aims to see if it is safe and may make treatment more effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have liver cancer and are planning to start immunotherapy.
- You are at least 20 years old.
- You are in good daily health (able to do light activities) — your doctor will check this.
- You have not had immunotherapy (like PD-1 or PD-L1 inhibitors) before.
- You do not have an active autoimmune disease (except for mild conditions like vitiligo or controlled thyroid issues).
- You are not taking high-dose steroids (more than 10 mg of prednisone daily) within 14 days of starting the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether changing the bacteria in your gut (with a probiotic) can help your current immunotherapy work better if your liver cancer has been growing. It's for people with advanced liver cancer who will continue their same immunotherapy despite the cancer progressing.
This study tests a combination of two treatments for advanced liver cancer (hepatocellular carcinoma): a bile acid supplement called tauroursodeoxycholic acid plus an immunotherapy drug (a PD-1/PD-L1 inhibitor) that helps your immune system fight the cancer. The goal is to see if this combination is safe and effective in people who have not yet had any whole-body cancer treatment.
This study is testing whether combining targeted therapy with immunotherapy (or using two immunotherapies together) can help people with liver cancer that cannot be surgically removed. The goal is to understand how well these treatments work and how they affect biomarkers (signals in your body that show treatment response).
This trial tests a combination of two treatments for advanced liver cancer: TACE (a procedure that blocks the blood supply to the tumor) and an anti-PD-1 antibody (a type of immunotherapy that helps your immune system fight cancer). The goal is to see if this combination works better than either treatment alone and to understand how it affects the immune system around the tumor.
This study tests whether taking a specific probiotic (Lactobacillus reuteri) before surgery, along with standard immunotherapy, helps treat liver cancer better. You would take the probiotic daily, then have immunotherapy, and later potentially surgery to remove the tumor.
This study tests a new combination treatment for liver cancer that cannot be removed by surgery. It combines a procedure called TACE (which delivers chemotherapy directly to the tumor) with an investigational drug, ivonescimab, which helps the immune system fight cancer. The goal is to see if this combination is safe and effective for people whose cancer has not spread beyond the liver.
Hear when a new Liver Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.